Fuels growth by enabling IVD test development and manufacturing for nCounter diagnostic platform Expands scientific capabilities into immuno-oncology and broadens diagnostics scope to 8 of the 10 top cancers by U.S. incidence SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug.
Total Revenue Increased 166% to $55.1 million ; Genomic Volume Grew 215% to 20,856 Tests Company Advanced Clinical Evidence, Pipeline and Global Growth Strategy Raises 2021 Total Revenue Guidance Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul.
Real-world data suggest Decipher test’s risk scores are independently associated with conversion to definitive treatment and with treatment failure SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 27, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced new data suggesting the Decipher ®
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 12, 2021-- Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced the appointment of Rebecca Chambers as executive vice president and chief financial officer. Ms. Chambers , a seasoned financial executive with a track
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 8, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today that it will release its financial results for the second quarter of 2021 after the close of market on Thursday, July 29 . Company management will host a conference call and webcast to
Rob Brainin Named Executive Vice President and Chief Business Officer; Bill Zondler Appointed Senior Vice President and Chief Information Officer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 8, 2021-- Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced key
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 1, 2021-- Veracyte (Nasdaq: VCYT), a global genomic diagnostics company, today announced key appointments that expand and further strengthen the company’s medical team. William A. Bulman , M.D. and Paul Kelly Marcom , M.D, have joined the company
First study demonstrating Decipher Prostate test can inform treatment decisions in nmCRPC SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 14, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced new data demonstrating the prognostic utility of the company’s Decipher ® Prostate genomic
First Molecular Subtyping Test to Gain Medicare Coverage to Inform Treatment for Individuals With Bladder Cancer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 4, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Medicare Administrative Contractors Palmetto GBA, WPS and CGS
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 2, 2021-- Details of the Raymond James Human Health Innovation Conference have been corrected. The updated release reads: VERACYTE TO PRESENT AT UPCOMING INVESTOR CONFERENCES Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company,
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
